(-0.12%) 5 462.50 points
(-0.35%) 38 976 points
(0.24%) 17 760 points
(0.33%) $81.10
(-3.48%) $2.66
(-0.94%) $2 308.90
(-0.37%) $28.76
(1.46%) $1 000.80
(0.29%) $0.936
(0.79%) $10.69
(0.42%) $0.792
(-0.21%) $87.30
Live Chart Being Loaded With Signals
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders...
Stats | |
---|---|
本日の出来高 | 1 198 |
平均出来高 | 0 |
時価総額 | 4.44M |
EPS | $-0.600 ( Q1 | 2024-05-08 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0100 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-29 | Silva Raul R. | Buy | 1 000 | Stock Option (right to Buy) |
2023-09-29 | Silva Raul R. | Buy | 10 000 | Stock Option (right to Buy) |
2023-09-15 | Callahan Jennifer L. | Buy | 5 000 | Common Stock |
2023-09-08 | Werth Peter J. | Buy | 6 838 235 | Pre-Funded Warrant (right to buy) |
2023-08-11 | Werth Peter J. | Buy | 1 823 155 | Common Stock |
INSIDER POWER |
---|
100.00 |
Last 79 transactions |
Buy: 10 002 264 | Sell: 8 300 |
Cingulate Inc. 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-582 918 (0.00 %) |
EPS: | $-26.01 |
FY | 2023 |
収益: | $0 |
総利益: | $-582 918 (0.00 %) |
EPS: | $-26.01 |
FY | 2022 |
収益: | $0 |
総利益: | $-621 993 (0.00 %) |
EPS: | $-31.57 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Cingulate Inc.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company\'s lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。